Reversal of Apixaban and Rivaroxaban Using Activated Prothrombin Complex Concentrates in Patients with Major Bleeding
Sign Up to like & getrecommendations! Published in 2019 at "American Journal of Cardiovascular Drugs"
DOI: 10.1007/s40256-019-00383-z
Abstract: Background Clinical experience with using activated prothrombin complex concentrates (aPCCs) to reverse the effects of factor Xa inhibitors is limited. Objectives Our objective was to assess the achievement of effective clinical hemostasis using aPCC in… read more here.
Keywords: apixaban rivaroxaban; major bleeding; activated prothrombin; hemostasis ... See more keywords
Activated prothrombin complex concentrates for direct oral anticoagulant-associated bleeding or urgent surgery: Hemostatic and thrombotic outcomes.
Sign Up to like & getrecommendations! Published in 2020 at "Thrombosis research"
DOI: 10.1016/j.thromres.2020.06.044
Abstract: INTRODUCTION Studies evaluating the use of activated prothrombin complex concentrates (aPCCs) for DOAC-associated bleeding are sparse. MATERIALS AND METHODS We conducted a retrospective study of patients receiving aPCC for DOAC-associated bleeding or for pre-operative optimization… read more here.
Keywords: urgent surgery; apcc; activated prothrombin; prothrombin complex ... See more keywords
Activated prothrombin complex concentrate to treat bleeding events in acquired hemophilia A: BAHAS study
Sign Up to like & getrecommendations! Published in 2022 at "European Journal of Haematology"
DOI: 10.1111/ejh.13853
Abstract: Activated prothrombin complex concentrate (aPCC) is a bypassing agent indicated to treat bleeds in patients with acquired hemophilia A (AHA). Nevertheless, its efficacy and safety in the real‐world setting have not often been addressed. read more here.
Keywords: complex concentrate; prothrombin complex; activated prothrombin; acquired hemophilia ... See more keywords
Safety of FEIBA and emicizumab (SAFE): Dose escalation study evaluating the safety of in vivo administration of activated prothrombin complex concentrate in haemophilia A patients on emicizumab
Sign Up to like & getrecommendations! Published in 2022 at "Haemophilia"
DOI: 10.1111/hae.14684
Abstract: Emicizumab is a humanized bispecific monoclonal antibody licensed for patients with severe haemophilia A. Breakthrough bleeding still occurs in patients on emicizumab and can be managed with recombinant factor VIIa (rFVIIa) or activated prothrombin complex… read more here.
Keywords: safety; complex concentrate; patients emicizumab; prothrombin complex ... See more keywords